Terms: = Lymphoma AND IKZF1, LyF-1, 10320, ENSG00000185811, Q13422, Hs_54452, hIk-1, ZNFN1A1, IKAROS AND Treatment
158 results:
1. Tyrosine kinase inhibitor resistance in de novo BCR::ABL1-positive BCP-ALL beyond kinase domain mutations.
van Outersterp I; Boer JM; van de Ven C; Reichert CEJ; Boeree A; Kruisinga B; de Groot-Kruseman HA; Escherich G; Sijs-Szabo A; Rijneveld AW; den Boer ML
Blood Adv; 2024 Apr; 8(8):1835-1845. PubMed ID: 38386975
[TBL] [Abstract] [Full Text] [Related]
2. Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and ikzf1/3 degrader NX-2127.
Montoya S; Bourcier J; Noviski M; Lu H; Thompson MC; Chirino A; Jahn J; Sondhi AK; Gajewski S; Tan YSM; Yung S; Urban A; Wang E; Han C; Mi X; Kim WJ; Sievers Q; Auger P; Bousquet H; Brathaban N; Bravo B; Gessner M; Guiducci C; Iuliano JN; Kane T; Mukerji R; Reddy PJ; Powers J; Sanchez Garcia de Los Rios M; Ye J; Barrientos Risso C; Tsai D; Pardo G; Notti RQ; Pardo A; Affer M; Nawaratne V; Totiger TM; Pena-Velasquez C; Rhodes JM; Zelenetz AD; Alencar A; Roeker LE; Mehta S; Garippa R; Linley A; Soni RK; Skånland SS; Brown RJ; Mato AR; Hansen GM; Abdel-Wahab O; Taylor J
Science; 2024 Feb; 383(6682):eadi5798. PubMed ID: 38301010
[TBL] [Abstract] [Full Text] [Related]
3. Combination of minimal residual disease on day 15 and copy number alterations results in BCR-ABL1-negative pediatric B-ALL: A powerful tool for prediction of induction failure.
Baghdadi H; Soleimani M; Zavvar M; Bahoush G; Poopak B
Cancer Genet; 2024 Apr; 282-283():27-34. PubMed ID: 38183785
[TBL] [Abstract] [Full Text] [Related]
4. Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL.
Bastian L; Beder T; Barz MJ; Bendig S; Bartsch L; Walter W; Wolgast N; Brändl B; Rohrandt C; Hansen BT; Hartmann AM; Iben K; Das Gupta D; Denker M; Zimmermann J; Wittig M; Chitadze G; Neumann M; Schneller F; Fiedler W; Steffen B; Stelljes M; Faul C; Schwartz S; Müller FJ; Cario G; Harder L; Haferlach C; Pfeifer H; Gökbuget N; Brüggemann M; Baldus CD
Blood; 2024 Apr; 143(14):1391-1398. PubMed ID: 38153913
[TBL] [Abstract] [Full Text] [Related]
5. Pre- and Postnatal Exposures to Tobacco Smoking and Survival of Childhood Acute Lymphoblastic and Myeloid Leukemias in California, United States.
Metayer C; Morimoto LM; Kang AY; Sanchez Alvarez J; Winestone LE
Cancer Epidemiol Biomarkers Prev; 2024 Jan; 33(1):117-125. PubMed ID: 37921440
[TBL] [Abstract] [Full Text] [Related]
6. Toblerone: detecting exon deletion events in cancer using RNA-seq.
Lonsdale A; Halman A; Brown L; Kosasih H; Ekert P; Oshlack A
F1000Res; 2023; 12():130. PubMed ID: 37767021
[TBL] [Abstract] [Full Text] [Related]
7. Genes of Predisposition to Childhood Beta-Cell Acute Lymphoblastic Leukemia in the Kazakh Population.
Svyatova G; Boranbayeva R; Berezina G; Manzhuova L; Murtazaliyeva A
Asian Pac J Cancer Prev; 2023 Aug; 24(8):2653-2666. PubMed ID: 37642051
[TBL] [Abstract] [Full Text] [Related]
8. Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study.
Kim R; Bergugnat H; Pastoret C; Pasquier F; Raffoux E; Larcher L; Passet M; Grardel N; Delabesse E; Kubetzko S; Caye-Eude A; Meyer C; Marschalek R; Lafage-Pochitaloff M; Thiebaut-Bertrand A; Balsat M; Escoffre-Barbe M; Blum S; Baumann M; Banos A; Straetmans N; Gallego-Hernanz MP; Chalandon Y; Graux C; Soulier J; Leguay T; Hunault M; Huguet F; Lhéritier V; Dombret H; Boissel N; Clappier E
Blood; 2023 Nov; 142(21):1806-1817. PubMed ID: 37595275
[TBL] [Abstract] [Full Text] [Related]
9.
Al-Zayan NR; Ashour MJ; Abuwarda HN; Sharif FA
Pediatr Hematol Oncol; 2024; 41(2):103-113. PubMed ID: 37578068
[TBL] [Abstract] [Full Text] [Related]
10. [Leukemia Genotype Analysis of Children with Acute Lymphoblastic Leukemia in Yunnan Area].
Shi SL; Kui LY; Xia SM; Zhou BL; Li RJ; Jiang HC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Aug; 31(4):980-984. PubMed ID: 37551465
[TBL] [Abstract] [Full Text] [Related]
11. Mechanism and therapeutic implications of pomalidomide-induced immune surface marker upregulation in EBV-positive lymphomas.
Jaeger HK; Davis DA; Nair A; Shrestha P; Stream A; Yaparla A; Yarchoan R
Sci Rep; 2023 Jul; 13(1):11596. PubMed ID: 37463943
[TBL] [Abstract] [Full Text] [Related]
12. Improved Outcome for ALL by Prolonging Therapy for
Pieters R; de Groot-Kruseman H; Fiocco M; Verwer F; Van Overveld M; Sonneveld E; van der Velden V; Beverloo HB; Bierings M; Dors N; de Haas V; Hoogerbrugge P; Van der Sluis I; Tissing W; Veening M; Boer J; Den Boer M
J Clin Oncol; 2023 Sep; 41(25):4130-4142. PubMed ID: 37459571
[TBL] [Abstract] [Full Text] [Related]
13. Dasatinib plus prednisone as induction and consolidation for adults with Ph-positive acute lymphoblastic leukaemia: A single-arm, multicentre, phase 2 trial.
Xie M; Lu Y; Ouyang G; Li X; Shi T; Yang M; Le J; Hu H; Zhang L; Feng W; Meng H; Mai W; Wei J; Qian J; Xu G; Yang C; Zhou D; Lin Y; Qian S; Kuang Y; Zhang L; Zhu W; Yao G; Wu G; Hu S; Huang X; Wang Y; Tong H; Jin J; Zhu HH
Br J Haematol; 2023 Sep; 202(6):1119-1126. PubMed ID: 37434414
[TBL] [Abstract] [Full Text] [Related]
14. 'Evaluation of adverse prognostic gene alterations & MRD positivity in BCR::ABL1-like B-lineage acute lymphoblastic leukaemia patients, in a resource-constrained setting.
Gupta DG; Varma N; Sreedharanunni S; Abdulkadir SA; Naseem S; Sachdeva MUS; Binota J; Bose P; Malhotra P; Khadwal A; Varma S
Br J Cancer; 2023 Jul; 129(1):143-152. PubMed ID: 37156894
[TBL] [Abstract] [Full Text] [Related]
15. Optical Genome Mapping Reveals and Characterizes Recurrent Aberrations and New Fusion Genes in Adult ALL.
Vieler LM; Nilius-Eliliwi V; Schroers R; Vangala DB; Nguyen HP; Gerding WM
Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980958
[TBL] [Abstract] [Full Text] [Related]
16. ikaros in Acute Leukemia: A Positive Influencer or a Mean Hater?
Conserva MR; Redavid I; Anelli L; Zagaria A; Tarantini F; Cumbo C; Tota G; Parciante E; Coccaro N; Minervini CF; Minervini A; Specchia G; Musto P; Albano F
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834692
[TBL] [Abstract] [Full Text] [Related]
17. [In vitro pharmacodynamic studies of novel class Ⅰ and Ⅱb selective histone deacetylase inhibitor purinostat mesylate in the treatment of diffuse large B-cell lymphoma and its mechanism].
Wang J; Zhao AL; Li H; Yang LY; Chen LJ; Niu T
Zhonghua Xue Ye Xue Za Zhi; 2022 Sep; 43(9):753-759. PubMed ID: 36709169
[No Abstract] [Full Text] [Related]
18. Integrative genomic analysis of childhood acute lymphoblastic leukaemia lacking a genetic biomarker in the UKALL2003 clinical trial.
Schwab C; Cranston RE; Ryan SL; Butler E; Winterman E; Hawking Z; Bashton M; Enshaei A; Russell LJ; Kingsbury Z; Peden JF; Barretta E; Murray J; Gibson J; Hinchliffe AC; Bain R; Vora A; Bentley DR; Ross MT; Moorman AV; Harrison CJ
Leukemia; 2023 Mar; 37(3):529-538. PubMed ID: 36550215
[TBL] [Abstract] [Full Text] [Related]
19. The kinetics of blast clearance are associated with copy number alterations in childhood B-cell acute lymphoblastic leukemia.
Urbańska Z; Lejman M; Taha J; Madzio J; Ostrowska K; Miarka-Walczyk K; Wypyszczak K; Styka B; Jakubowska J; Sędek Ł; Szczepański T; Stańczak M; Fendler W; Młynarski W; Pastorczak A
Neoplasia; 2023 Jan; 35():100840. PubMed ID: 36288679
[TBL] [Abstract] [Full Text] [Related]
20. Integrated clinical genotype-phenotype characteristics of early T-cell precursor acute lymphoblastic leukemia.
Ye MT; Wang Y; Zuo Z; Calin S; He H; Tang Z; Jabbour EJ; Borthakur G; Zhang Y; Yang Y; You MJ
Cancer; 2023 Jan; 129(1):49-59. PubMed ID: 36281717
[TBL] [Abstract] [Full Text] [Related]
[Next]
